Form 8-K - Current report:
SEC Accession No. 0001193805-23-000064
Filing Date
2023-01-20
Accepted
2023-01-19 21:30:25
Documents
15
Period of Report
2023-01-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K e618207_8k-immunic.htm   iXBRL 8-K 25022
2 e618207_ex10-1.htm EX-10.1 17967
3 e618207_ex10-2.htm EX-10.2 17723
4 e618207_ex10-3.htm EX-10.3 18111
  Complete submission text file 0001193805-23-000064.txt   268958

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE imux-20230116.xsd EX-101.SCH 3215
6 XBRL LABEL FILE imux-20230116_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE imux-20230116_pre.xml EX-101.PRE 22351
9 EXTRACTED XBRL INSTANCE DOCUMENT e618207_8k-immunic_htm.xml XML 3809
Mailing Address 1200 AVENUE OF THE AMERICAS SUITE 200 NEW YORK X1 10036
Business Address 1200 AVENUE OF THE AMERICAS SUITE 200 NEW YORK X1 10036 (332) 255-9818
IMMUNIC, INC. (Filer) CIK: 0001280776 (see all company filings)

EIN.: 562358443 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36201 | Film No.: 23538771
SIC: 2834 Pharmaceutical Preparations